Given the $125 million run rate commitment for value creation initiatives by year-end, why is consensus modeling significantly lower EBIT growth for H2?

Management reaffirmed the $125 million run rate commitment, stating that in-year improvements will be realized towards the end of the year. They also highlighted that prior year's H2 included significant remeasurement gains ($28 million in Q3 2025) which will not recur in 2026, impacting year-over-year comparisons. “Keep in mind also that if you're looking purely at year-over-year results, last year, we did have some fairly significant remeasurement gains in the second half of the year, specifically a $28 million gain in the third quarter that is necessary to normalize for.”

Can you elaborate on the 40% gross margin cost savings (pricing vs. higher-margin products) and opportunities for specialty growth beyond 2026?

Gross margin improvements come from dynamic pricing strategies and strong growth in higher-margin corporate/own brands. In specialty, new products and the majority stake in SIN 360 are expected to drive growth, especially in the value implant segment in the U.S. and continued strong performance in European premium implants. “it includes our initiatives around improving our gross profit, leveraging data better to have a more dynamic view of our pricing, not dynamic pricing, but -- our pricing is more dynamic and finding opportunities to both raise price where it makes sense and opportunities to lower prices on things in order to drive more volume.”

Will U.S. dental equipment see year-over-year growth in H2, and what are the trends between traditional and digital equipment?

Management expects U.S. dental equipment growth in Q3 and Q4, supported by strong bookings. Digital equipment saw low single-digit growth in Q2 despite lower average selling prices for scanners, with good volume growth. Traditional equipment sales are expected to recover, with good visibility from the backlog. “We did see -- in the U.S., we did see low double -- I'm sorry, low single-digit growth in digital in the quarter. And that's despite some ongoing lower average selling prices, for example, with scanners.”

HSIC

Henry Schein (HSIC) Q2 FY26 earnings call: guidance and Q&A

Q: What are the components of U.S. dental consumables growth (volume vs. price/mix) and can the current growth rate be sustained in H2 despite tougher comps?

Management noted more price than volume in consumables growth. They expect a similar growth range in H2, driven by successful promotions converting episodic buyers to active customers, despite tougher comparables. “Last year, we did some promotions, started in the second half of the year. We really went after some of our episodic customers or customers who were not consistently buying from us. And that promotion and those promotions seem to really work and where we've really converted many of those customers and to actively engage customers that are continuing to buy from us.”

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

Henry Schein Q2 FY26 — Strong Sales and Margin Expansion Drive Raised Full-Year Guidance

Henry Schein delivered a strong second quarter, marked by accelerating internal local currency sales growth and significant margin expansion across all segments. The company is actively pursuing strategic priorities focused on accelerating growth, simplifying operations, and driving operational rigor, underpinned by value creation initiatives. Management raised its full-year 2026 guidance, reflecting confidence in sustained momentum and the benefits from these strategic efforts, while also highlighting the increasing contribution of high-growth, high-margin businesses.

Highlights

Internal local currency sales growth accelerated to 4.6% in Q2 FY26.
Non-GAAP operating income grew 10.5% in Q2 FY26.
Non-GAAP diluted EPS grew 15.5% to $1.27 in Q2 FY26.
Value creation initiatives are on track to deliver over $200 million in operating income improvements, with a $125 million run rate by end of 2026.
Henry Schein One's cloud-based platforms (Dentrix Ascend, Dentale) now serve almost 13,000 customers, with 90% recurring revenue.

Concerns

U.S. dental equipment sales declined 1.1% in Q2 FY26 due to tough comparables from prior year dental school orders.
Lower demand for point-of-care diagnostic products continued to be a headwind for the U.S. medical business.
Foreign currency exchange favorably impacted Q2 diluted EPS by only $0.01, and no further remeasurement gains are expected for the remainder of 2026.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Total Sales Growth	4.5% to 5.5% over 2025 high materiality	FY26	High
Full-year 2026 Internal Local Currency Sales Growth (H2)	3.5% to 4.5% medium materiality	H2 FY26	High
Full-year 2026 Non-GAAP Diluted EPS	$5.29 to $5.39 high materiality	FY26	High
Value Creation Initiatives Operating Income Improvement	greater than $200 million high materiality	Next few years	High
Value Creation Initiatives Operating Income Improvement Run Rate	$125 million high materiality	End of 2026 · FY26	High
Full-year 2026 Non-GAAP Effective Tax Rate	approximately 24% medium materiality	FY26	High
Full-year 2026 Adjusted EBITDA Growth	mid- to high single digits high materiality	FY26	High
Operating Cash Flow	exceed net income medium materiality	FY26	High
Earnings Growth	exceed that in the third quarter medium materiality	Q4 FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Global Distribution and Value-Added Services Group Reflecting good sales momentum across most regions.	—	6.6%	—	—
U.S. Dental Merchandise Growth from a combination of pricing and increased volume, with market share gains and stable patient traffic. Internal local currency sales growth: 6.5%	—	8.3%	—	—
U.S. Dental Equipment Primarily due to lower traditional equipment sales growth, impacted by large dental school orders in prior year. Modest growth in digital equipment.	—	-1.1%	—	—
U.S. Medical Distribution Despite continued headwinds in point-of-care diagnostic product sales, strong growth in government-related businesses and Home Solutions.	—	3.8%	—	—
International Dental Merchandise Driven by sales growth in Canada, France, Brazil, and Australia. Internal local currency sales growth: 5.4%	—	11.1%	—	—
International Dental Equipment Good sales growth in traditional equipment with modest growth in digital equipment, especially strong in Canada, Germany, Spain, and the U.K. Internal local currency sales growth: 5.4%	—	8.7%	—	—
Global Value-Added Services Driven by business solutions services in U.S. and internationally, partially offset by lower financial service revenues in the U.S. Internal local currency sales growth: 3.7%	—	5.1%	—	—
Global Specialty Products Group Sales growth driven by implants and biomaterials in both premium and value products. Operating margins expanded nicely, with a significant majority of profit growth being organic. Internal local currency sales growth: 3.2%	—	8.7%	—	—
Global Technology Group Strong revenue growth in Dentrix Ascend in the U.S. and Dentale cloud-based software internationally. Internal local currency sales growth: 9.1%	—	8.2%	—	—

HSIC operating KPIs by quarter

HSIC operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2025 Q4 FY25	Mar 2026 Q1 FY26	This call Jun 2026 Q2 FY26	Change vs prior quarter
Dentrix Ascend and Dentally subscribers	11K+ And now we have more than 11,000 Dentrix Ascend and Dentally subscribers, of course, the largest installed base in the world. Source: earnings call transcript	13K+ The number of cloud-based customers increased by roughly 25% year-over-year, primarily from new accounts, and we now have more than 13,000 Dentrix Ascend and Dentale subscribers. Source: earnings call transcript	<13K Almost 13,000 customers now subscribe to our Dentrix Ascend and Dentale cloud-based platforms, and we're seeing more customers move toward our higher-featured packages, which is increasing our monthly revenue per customer. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

Product	Type	Timeline	Details
MCP layer for AI applications	launch	Coming soon

Risks & headwinds

Lower demand for point-of-care diagnostic products Q2 FY26, ongoing

Continued headwinds

Mitigation:Focus on underlying growth in other medical segments like government-related and Home Solutions.

Tough comparable for U.S. dental equipment sales Q2 FY26

-1.1% decline in Q2 FY26

Mitigation:Strong backlog and expectation for U.S. equipment growth for the rest of the year.

Lower average selling prices for scanners Q2 FY26, ongoing

Ongoing lower average selling prices

Mitigation:Seeing good volume growth on scanners, with demand shifting towards lower-priced entries.

Higher prior year comparison in H2 FY26 H2 FY26

Higher prior year comparison

Mitigation:Expect internal local currency sales growth of 3.5% to 4.5% in H2, compared to 3.6% in H1, indicating continued momentum despite the tougher comp.

Lower remeasurement gains than originally anticipated FY26

$11 million expected for FY26 (already recorded in Q1) vs. $38 million in FY25

Mitigation:Guidance adjusted to reflect this, focusing on underlying business growth without additional remeasurement gains.

What to watch in Q3 FY26

Value Creation Initiatives Operating Income Improvement Run Rate

by end of 2026

Current On track for $125 million

Target $125 million run rate

Why it matters

This is a key commitment for operational efficiency and profitability improvement, directly impacting future earnings growth.

We continue to expect to achieve our goal of achieving greater than $200 million of operating income improvement resulting from our value creation initiatives with a $125 million run rate by the end of 2026

Find out whether HSIC delivers this. Inve re-checks your case every morning.

Q&A highlights

What are the components of U.S. dental consumables growth (volume vs. price/mix) and can the current growth rate be sustained in H2 despite tougher comps?

Management noted more price than volume in consumables growth. They expect a similar growth range in H2, driven by successful promotions converting episodic buyers to active customers, despite tougher comparables.

“Last year, we did some promotions, started in the second half of the year. We really went after some of our episodic customers or customers who were not consistently buying from us. And that promotion and those promotions seem to really work and where we've really converted many of those customers and to actively engage customers that are continuing to buy from us.”

asked by Jeffrey Johnson · answered by Frederick Lowery

2 min read 6 chapters

Detailed narrative

New CEO's Strategic Priorities and Vision

Fred Lowery, in his first month as CEO, outlined key priorities: accelerating growth, simplifying the business, driving operational rigor, and deepening customer relationships. He emphasized transforming Henry Schein into a 'practice improvement platform' for healthcare practitioners, moving beyond a traditional distributor role.

The vision includes leveraging technology and data to optimize customer operations, enhance profitability, and deliver better patient care, aiming for accelerated growth and expanded market share.

Henry Schein One Technology and AI Innovation

The Global Technology Group, Henry Schein One, continues strong growth, particularly with its cloud-based platforms like Dentrix Ascend and Dentale, which now serve almost 13,000 customers. The company is embedding AI tools into its software to improve workflows, collections, practice performance, and patient engagement.

A new AI clinical workflow has been launched, and an upcoming MCP layer will enable practices to query their own data for revenue opportunities and operational efficiencies, reinforcing Henry Schein's leadership in AI transformation.

Value Creation Initiatives and Operational Rigor

Henry Schein is on track to achieve over $200 million in operating income improvements from value creation initiatives over the next few years, with a $125 million run rate by the end of 2026. Key initiatives include implementing global outsourcing for finance and customer service (expected to deliver over half of G&A savings), centralizing indirect procurement, and using sales data for dynamic pricing.

These efforts aim to create a high-performance culture of accountability and continuous improvement, driving double-digit earnings growth next year.

Market Share Gains and Product Performance

The company reported strong performance in its dental merchandise business globally, outpacing the market and gaining share. This was attributed to the growth of corporate and exclusive brands (e.g., Edge in endodontics, uridine), a strong position in the fast-growing DSO segment, and successful promotions converting episodic buyers into actively engaged customers. International markets like Canada, France, Brazil, and Australia showed particularly strong growth.

Specialty Products and Medical Business Expansion

Specialty products sales were solid, with high single-digit implant growth in Europe, led by premium brands like Camlog. U.S. implant growth was more modest but driven by value implants (SIN 360) and new product launches (SIN 360, Tapered Pro Conifer).

The medical business saw good underlying growth despite headwinds in point-of-care diagnostics, with strong performance in government-related and high single-digit growth in the Home Solutions business, an area of continued strategic focus due to its higher growth and margins.

Leadership Team Changes

The company announced changes to its executive management committee, aimed at fostering closer customer relationships, increasing decision-making speed, and improving execution consistency. This involved removing a management layer and integrating the supply chain more deeply into the distribution business. Three long-serving executives transitioned to senior advisor roles, ensuring continuity and leveraging their experience.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.